AMERICAN COLLEGE OF SURGEONS ONCOLOGY GROUP

美国外科学院肿瘤学组

• 批准号: 6763035
• 负责人: SAMUEL A WELLS
• 金额: $ 352.26万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-15 至 2004-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6763035
• 关键词: biomarker; breast neoplasms; cancer prevention; cancer risk; clinical research; clinical trials; combination cancer therapy; cooperative study; esophagus neoplasm; human subject; human therapy evaluation; intestine neoplasm; lung neoplasms; melanoma; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer palliative treatment; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; retinoblastoma

The American College of Surgeons Oncology Group (ACOSOG) was recently established to define the role of surgical therapies in patients with malignant solid tumors. The ACOSOG incorporates general and specialty surgical oncologists, and non-surgical oncologists, in academic medical centers and community practice throughout the United States of America and in foreign countries. This surgical group is important to the oncological community because of the primary role of surgery in the treatment of the cancer patient. Also the interrelationship of the ACOSOG with the American College of Surgeons (ACOS) provides a unique opportunity to utilize evidenced based medicine to educate large number of surgeons in the standard of care for the cancer patient. ACOSOG trials will evaluate several areas of surgical and basic oncology. The most important are: a) new and existing operative procedures; b) new technology and devices, c) diagnostic molecular markers and therapeutic biologic agents, d) radiographic imaging procedures, and e) interventional therapy in patients demonstrated to have a genetic predisposition for cancer. ACOSOG will also perform multimodality therapeutic trials in patients with certain solid tumors that are less accessible to other cooperative groups because they are uncommon and are treated primarily by surgical resection. ACOSOG will participate in Intergroup studies when the Group's resources and access to surgical patients can substantially enhance accrual to those trials. ACOSOG benefits from its strong relationship with the American College of Surgeons (ACS), the largest organization of surgeons in the world with broad geographic membership including general and specialty surgeons in both academic and private practice. This broad membership also positions ACOSOG to offer clinical trials to women, minorities and underserved populations. In addition, for purposes of institutional auditing and physician education, ACOSOG will interact closely with the Commission on Cancer (COC) of the ACS which has a large staff serving the Cancer Programs of almost 1500 approved hospitals across North America. ACOSOG is committed to lowering cancer incidence and mortality through innovative clinical trials that allow broad physician and patient participation.

美国外科医学院肿瘤学小组(ACOSOG)最近 为明确外科治疗在慢性阻塞性肺疾病患者中的作用而设立 恶性实体瘤。ACOSOG集一般和专业于一身 外科肿瘤学家和非外科肿瘤学家，学术医学 全美各地的中心和社区实践活动 外国。这个手术小组对肿瘤学来说很重要 社区因为外科手术在治疗中的主要作用 癌症患者。也谈ACOSOG与美国的相互关系 外科医生学院(ACOS)提供了一个独特的机会来利用证据 以基础医学为基础，对大批外科医生进行护理标准的教育 癌症患者。 ACOSOG试验将评估外科和基础肿瘤学的几个领域。这个 最重要的是：a)新的和现有的手术程序；b)新的 技术和设备，c)诊断分子标记和治疗 生物制剂，d)放射成像程序，和e)介入 患者的治疗被证明具有患癌症的遗传易感性。 ACOSOG还将对患有以下疾病的患者进行多模式治疗试验 其他合作小组不易接触到的某些实体肿瘤 因为它们不常见，主要通过手术切除来治疗。 ACOSOG将参与小组间研究，当小组的资源和 接触外科患者可以极大地增加这些试验的收益。 ACOSOG受益于它与美国科学院的密切关系 外科医生(ACS)，世界上最大的外科医生组织，拥有广泛的 地域成员包括普通外科医生和专科外科医生 学术和私人实践。这一广泛的成员资格也使ACOSOG能够 向妇女、少数民族和未得到充分服务的人群提供临床试验。在……里面 此外，为了机构审计和医生教育的目的， ACOSOG将与美国癌症协会癌症委员会(COC)密切互动 它有大量的工作人员为近1500个获得批准的癌症项目服务 北美各地的医院。 ACOSOG致力于通过以下方式降低癌症发病率和死亡率 创新的临床试验，允许广泛的医生和患者 参与。